Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Alisertib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 15 Jun 2018 Status changed from suspended to recruiting.
- 03 Apr 2018 Status changed from recruiting to suspended.
- 29 Nov 2017 Planned End Date changed from 1 Dec 2021 to 15 Dec 2021.